Teva Pharmaceutical Industries - 10 Largest U.S. Patent Losses

Drug: Provigil
Company: Teva Pharmaceutical Industries (via Cephalon buyout)
2010 U.S. sales: $1.059 billion/$1.120 billion global
Impact: 10.6% of Teva's U.S. sales, 49.4% of Cephalon's
Exclusivity expires: April 2012

You might say Cephalon dodged a bullet on its Provigil patent loss. The company was set to lose almost half of its U.S. sales when the blockbuster narcolepsy drug lost exclusivity. Provigil amounted to almost 40% of Cephalon's worldwide revenues, too. Although Cephalon had a follow-up drug, Nuvigil, already on the market, the company knew its numbers would take a big hit.

Cephalon raised Provigil's price to capitalize on the brand as much as possible--and inspire patients to convert to Nuvigil instead. It struck deals with generics makers, some of which attracted scrutiny from antitrust regulators. It sought new indications for the wakefulness drugs--and found itself under investigation by the Justice Department for potential off-label marketing violations.

Now, Cephalon is part of Teva Pharmaceutical Industries. Suddenly, the loss of Provigil exclusivity isn't as big of a problem. The drug's $1 billion-plus sales do amount to 10% of Teva's North American revenues, but the company has other big growth plans to compensate. In fact, Teva agreed to divest its generic version of Provigil in Europe--and to sell one-year generic rights in the U.S. to Par Pharmaceutical. No, Teva's biggest patent worry isn't Provigil. It's Copaxone, but that's not until 2014.

Teva Pharmaceutical Industries - 10 Largest U.S. Patent Losses

Suggested Articles

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.